Accessibility navigation

Katacine is a new ligand of CLEC-2 that acts as a platelet agonist

Morán, L. A., Di, Y., Sowa, M. A., Hermida-Nogueira, L., Barrachina, M. N., Martin, E., Clark, J. C., Mize, T. H., Eble, J. A., Moreira, D., Pollitt, A. Y., Loza, M. I., Domínguez, E., Watson, S. P. and Garcia, Á. (2022) Katacine is a new ligand of CLEC-2 that acts as a platelet agonist. Thrombosis and haemostasis, 122 (8). pp. 1361-1368. ISSN 0340-6245

Text (open access) - Published Version
· Available under License Creative Commons Attribution Non-commercial No Derivatives.
· Please see our End User Agreement before downloading.

[img] Text - Accepted Version
· Restricted to Repository staff only


It is advisable to refer to the publisher's version if you intend to cite from this work. See Guidance on citing.

To link to this item DOI: 10.1055/a-1772-1069


Background: CLEC-2 is a platelet receptor with an important role in thrombo-inflammation but a minor role in haemostasis. Two endogenous ligands of CLEC-2 have been identified, the transmembrane protein podoplanin, and iron-containing porphyrin hemin, which is formed following haemolysis from red blood cells. Other exogenous ligands such as rhodocytin have contributed to our understanding of the role of CLEC-2. Objectives: To identify novel CLEC-2 small molecule ligands to aid therapeutic targeting of CLEC-2. Methods: ALPHA Screen technology has been used for development of a high throughput screening (HTS) assay recapitulating the podoplanin-CLEC-2 interaction. Light transmission aggregometry was used to evaluate platelet aggregation. Immunoprecipitation and western blot were used to evaluate direct phosphorylation of CLEC-2 and downstream protein phosphorylation. Autodock vina software was used to predict the molecular binding site of katacine and mass spectrometry to determine the polymeric nature of the ligand. Results and conclusions: We developed a CLEC-2-podoplanin interaction assay in a HTS format and screened 5016 compounds from an EU-Open screen library. We identified katacine, a mixture of polymers of proanthocyanidins, as a novel ligand for CLEC-2 and showed that it induces platelet aggregation and CLEC-2 phosphorylation via Syk- and Src kinases. Platelet aggregation induced by katacine is inhibited by the anti-CLEC-2 monoclonal antibody fragment AYP1 F(ab)’2. Katacine is a novel non-protein ligand of CLEC-2 that could contribute to a better understanding of CLEC-2 activation in human platelets.

Item Type:Article
Divisions:Life Sciences > School of Biological Sciences > Biomedical Sciences
ID Code:102388
Publisher:Cambridge University Press


Downloads per month over past year

University Staff: Request a correction | Centaur Editors: Update this record

Page navigation